查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1397047

TAVR栓塞防护的全球市场：按产品：机会分析和产业预测（2023-2032 年）

TAVR Embolic Protection Market By Product (SENTINEL cerebral protection system, TriGUARD 3 CEP device technology): Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 140 Pages | 商品交期: 2-3个工作天内

价格

预计2022年全球TAVR栓塞防护市场规模将达到108,782,530美元，2023年至2032年复合年增长率为14%，2032年将达到405,440,670美元。

经导管主动脉瓣置换术（TAVR）栓塞防护装置是TAVR手术期间使用的专用医疗设备。

TAVR 是一种微创外科手术，旨在治疗主动脉瓣狭窄，即心臟主动脉瓣狭窄并限制血流的疾病。 TAVR 通常涉及透过导管将新的人工瓣膜插入心臟，从而避免进行心臟直视手术。

TAVR 手术中使用的栓塞防护装置专门设计用于捕捉和防止手术过程中可能脱落的栓塞碎片（小颗粒和血块）。这些栓塞碎片可以在血流中传播，对包括大脑在内的其他器官造成阻塞或损伤，导致中风和器官损伤等併发症。

TAVR栓塞保护装置的主要功能是透过捕捉和容纳瓣膜置换手术期间可能脱落的碎片来降低栓塞风险。这些装置通常由过滤器或网状结构组成，插入血管中并在栓塞物质造成伤害之前将其捕获。 TAVR栓塞防护市场的成长主要是由于心血管疾病（尤其是主动脉瓣狭窄）盛行率的上升和老年人口的扩大所推动的。

例如，2021 年美国国家医学图书馆发表的一篇论文发现，主动脉瓣狭窄 (AVS) 是一种常见的心臟瓣膜疾病，盛行率随着老龄化的增长而增加，约 13.2% 受影响。这种疾病的特征是瓣膜小叶中形成疤痕和钙积聚。

老年族群中主动脉瓣狭窄的盛行率不断增加，他们经常选择TAVR等微创手术，这是推动脑栓塞防护设备需求的关键因素。这些装置对于最大限度地减少 TAVR 手术期间栓塞碎片移位相关的併发症至关重要。因此，对于更容易患心血管疾病的老年人来说，TAVR作为主动脉瓣狭窄的治疗选择越来越受欢迎，这刺激了对脑栓塞防护设备的需求并推动市场成长。

然而，限制市场成长的因素包括手术复杂性和 TAVR栓塞保护的高成本。这些设备的使用通常需要对医疗专业人员进行专门培训，这给实施带来了挑战。此外，与栓塞防护装置相关的高成本可能是一个主要的阻碍力，特别是在医疗保健预算有限的地区。

因此，必须努力简化手术、降低成本，使栓塞防护装置更为医疗专业人员和患者所熟悉。此外，由于政府机构和主要产业参与者加强开发先进医疗设备的配合措施，该市场具有潜在的成长潜力。这些配合措施旨在提高栓塞防护装置的安全性和有效性，并可能改善患者的治疗效果。

目录

第一章简介

第 2 章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 死亡率下降
      • TAVR栓塞防护装置的技术进步
      • 扩大微创手术的采用
    • 抑制因素
      • 产品缺陷和召回
      • 手术的复杂性
    • 机会
      • 越来越重视研究和开发

第 4 章 TAVR栓塞防护市场：依产品

  • 概述
  • SENTINEL 大脑保护系统
  • TriGUARD 3 CEP 设备技术

第五章 TAVR栓塞防护市场：依地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 其他的
  • 拉丁美洲/中东/非洲
    • 拉丁美洲
    • 中东/非洲

第六章竞争形势

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争仪表板
  • 竞争热图
  • 主要企业定位（2022年）

第七章 公司简介

  • Boston Scientific Corporation
  • Edward Lifesciences Corporation
  • Filterlex Medical Ltd.
  • Protembis GmbH
  • Innovative Cardiovascular Solutions, LLC.
  • EnCompass Technologies, Inc.
  • Transverse Medical Inc.
  • Emboline, Inc.
  • Cardioptimus
  • Venus MedTech HangZhou Inc.
Product Code: A74414

The TAVR embolic protection market was valued for $108,782.53 thousand in 2022 and is estimated to reach $405,440.67 thousand by 2032, exhibiting a CAGR of 14% from 2023 to 2032.

Transcatheter aortic valve replacement (TAVR) embolic protection devices are specialized medical devices used during TAVR procedures. TAVR is a minimally invasive surgical technique designed to treat aortic valve stenosis, a condition in which the aortic valve in the heart becomes narrowed and obstructs blood flow. During TAVR, a new artificial valve is typically inserted into the heart through a catheter, avoiding the need for open-heart surgery.

Embolic protection devices used in TAVR procedures are specifically designed to capture and prevent the release of embolic debris (small particles or clots) that may break loose during the procedure. These embolic debris can potentially travel through the bloodstream and cause blockages or damage to other organs, including the brain, which can lead to complications such as stroke or organ damage.

The primary function of TAVR embolic protection devices is to reduce the risk of embolic events by capturing and containing any debris that might dislodge during the valve replacement procedure. These devices often consist of filters or mesh-like structures that are inserted into blood vessels to catch and trap any embolic material before it can cause harm. The growth of the TAVR embolic protection market is primarily driven by rise in incidence of cardiovascular diseases, particularly aortic valve stenosis, and the expanding geriatric population.

For instance, according to an article published in the National Library of Medicine, in 2021, aortic valve stenosis (AVS) is a common heart valve condition that becomes more prevalent with age, affecting approximately 13.2% of patients aged 75 and older. This condition is characterized by the scarring and accumulation of calcium in the valve cusp.

The growing prevalence of aortic valve stenosis in the elderly population, who often choose minimally invasive procedures such as TAVR, is a key factor driving the demand for cerebral embolic protection devices. These devices are essential for minimizing complications associated with the dislodgment of embolic debris during TAVR procedures. Thus, rise in preference for TAVR as a treatment option for aortic valve stenosis among elderly patients, who are more susceptible to cardiovascular diseases, fuels the demand for cerebral embolic protection devices and thereby drives the market growth.

However, factors that hamper the market growth include procedural complexities and high costs TAVR embolic protection devices. Utilization of these devices often requires specialized training for healthcare professionals, contributing to the challenge of implementation. In addition, the high cost associated with cerebral embolic protection devices can be a significant deterrent, particularly in regions with limited healthcare budgets.

Thus, the combination of these factors can hinder widespread adoption and market growth, necessitating efforts to simplify procedures and reduce costs to make these devices more accessible to healthcare providers and patients. Furthermore, the market is poised for potential growth, owing to a rise in initiatives undertaken by government organizations and key industry players in the development of advanced devices. These collaborative efforts aim to enhance the safety and effectiveness of cerebral embolic protection devices, which can lead to better patient outcomes.

In addition, ongoing clinical trials focused on improving these devices are expected to yield promising results. These developments are anticipated to create lucrative opportunities for the market expansion during the forecast period, as they can lead to the introduction of more innovative and efficient cerebral embolic protection solutions, meeting the evolving needs of healthcare providers and patients.

The TAVR embolic protection market is segmented into product type and region. By product type, the market is categorized into SENTINEL cerebral protection system and TriGUARD 3 CEP device technology. Region-wise, the market is analyzed across North America (the U.S. and Canada), Europe (Germany, France, the UK, Italy, and rest of Europe), Asia-Pacific (Japan, China, Australia, India and rest of Asia-Pacific), and LAMEA (Latin America and Middle East & Africa).

The key players operating in the TAVR embolic protection market are Boston Scientific Corporation, Edward Lifesciences Corporation, Filterlex Medical Ltd., Innovative Cardiovascular Solutions, LLC., Protembis GmbH, Transverse Medical Inc., Emboline, Inc., Cardioptimus ,EnCompass Technologies, Inc., and Venus MedTech HangZhou Inc. The key players have adopted strategies such as product approval, funding and clinical trials to enhance their product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the tavr embolic protection market analysis from 2022 to 2032 to identify the prevailing tavr embolic protection market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the tavr embolic protection market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global tavr embolic protection market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Historic market data

Key Market Segments

By Product

  • SENTINEL cerebral protection system
  • TriGUARD 3 CEP device technology

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East And Africa

Key Market Players:

    • Protembis GmbH
    • Innovative Cardiovascular Solutions, LLC.
    • Filterlex Medical Ltd.
    • Cardioptimus
    • Transverse Medical Inc.
    • Venus MedTech HangZhou Inc.
    • EnCompass Technologies, Inc.
    • Boston Scientific Corporation
    • Edward Lifesciences Corporation
    • Emboline, Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Reduced mortality rate
      • 3.4.1.2. Technological advancements in TAVR embolic protection devices
      • 3.4.1.3. Growing adoption of minimally invasive procedures
    • 3.4.2. Restraints
      • 3.4.2.1. Product failure and recalls
      • 3.4.2.2. Procedural Complexity
    • 3.4.3. Opportunities
      • 3.4.3.1. Growing focus on Research and development

CHAPTER 4: TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. SENTINEL cerebral protection system
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. TriGUARD 3 CEP device technology
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: TAVR EMBOLIC PROTECTION MARKET, BY REGION

  • 5.1. Overview
    • 5.1.1. Market size and forecast By Region
  • 5.2. North America
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by Product
    • 5.2.3. Market size and forecast, by country
      • 5.2.3.1. U.S.
      • 5.2.3.1.1. Market size and forecast, by Product
      • 5.2.3.2. Canada
      • 5.2.3.2.1. Market size and forecast, by Product
  • 5.3. Europe
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by Product
    • 5.3.3. Market size and forecast, by country
      • 5.3.3.1. Germany
      • 5.3.3.1.1. Market size and forecast, by Product
      • 5.3.3.2. France
      • 5.3.3.2.1. Market size and forecast, by Product
      • 5.3.3.3. UK
      • 5.3.3.3.1. Market size and forecast, by Product
      • 5.3.3.4. Italy
      • 5.3.3.4.1. Market size and forecast, by Product
      • 5.3.3.5. Rest of Europe
      • 5.3.3.5.1. Market size and forecast, by Product
  • 5.4. Asia-Pacific
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by Product
    • 5.4.3. Market size and forecast, by country
      • 5.4.3.1. Japan
      • 5.4.3.1.1. Market size and forecast, by Product
      • 5.4.3.2. China
      • 5.4.3.2.1. Market size and forecast, by Product
      • 5.4.3.3. India
      • 5.4.3.3.1. Market size and forecast, by Product
      • 5.4.3.4. Australia
      • 5.4.3.4.1. Market size and forecast, by Product
      • 5.4.3.5. Rest of Asia-Pacific
      • 5.4.3.5.1. Market size and forecast, by Product
  • 5.5. LAMEA
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by Product
    • 5.5.3. Market size and forecast, by country
      • 5.5.3.1. Latin America
      • 5.5.3.1.1. Market size and forecast, by Product
      • 5.5.3.2. Middle East And Africa
      • 5.5.3.2.1. Market size and forecast, by Product

CHAPTER 6: COMPETITIVE LANDSCAPE

  • 6.1. Introduction
  • 6.2. Top winning strategies
  • 6.3. Product mapping of top 10 player
  • 6.4. Competitive dashboard
  • 6.5. Competitive heatmap
  • 6.6. Top player positioning, 2022

CHAPTER 7: COMPANY PROFILES

  • 7.1. Boston Scientific Corporation
    • 7.1.1. Company overview
    • 7.1.2. Key executives
    • 7.1.3. Company snapshot
    • 7.1.4. Operating business segments
    • 7.1.5. Product portfolio
    • 7.1.6. Business performance
  • 7.2. Edward Lifesciences Corporation
    • 7.2.1. Company overview
    • 7.2.2. Key executives
    • 7.2.3. Company snapshot
    • 7.2.4. Operating business segments
    • 7.2.5. Product portfolio
    • 7.2.6. Business performance
  • 7.3. Filterlex Medical Ltd.
    • 7.3.1. Company overview
    • 7.3.2. Key executives
    • 7.3.3. Company snapshot
    • 7.3.4. Operating business segments
    • 7.3.5. Product portfolio
    • 7.3.6. Key strategic moves and developments
  • 7.4. Protembis GmbH
    • 7.4.1. Company overview
    • 7.4.2. Key executives
    • 7.4.3. Company snapshot
    • 7.4.4. Operating business segments
    • 7.4.5. Product portfolio
    • 7.4.6. Key strategic moves and developments
  • 7.5. Innovative Cardiovascular Solutions, LLC.
    • 7.5.1. Company overview
    • 7.5.2. Key executives
    • 7.5.3. Company snapshot
    • 7.5.4. Operating business segments
    • 7.5.5. Product portfolio
  • 7.6. EnCompass Technologies, Inc.
    • 7.6.1. Company overview
    • 7.6.2. Key executives
    • 7.6.3. Company snapshot
    • 7.6.4. Operating business segments
    • 7.6.5. Product portfolio
    • 7.6.6. Key strategic moves and developments
  • 7.7. Transverse Medical Inc.
    • 7.7.1. Company overview
    • 7.7.2. Key executives
    • 7.7.3. Company snapshot
    • 7.7.4. Operating business segments
    • 7.7.5. Product portfolio
  • 7.8. Emboline, Inc.
    • 7.8.1. Company overview
    • 7.8.2. Key executives
    • 7.8.3. Company snapshot
    • 7.8.4. Operating business segments
    • 7.8.5. Product portfolio
    • 7.8.6. Key strategic moves and developments
  • 7.9. Cardioptimus
    • 7.9.1. Company overview
    • 7.9.2. Key executives
    • 7.9.3. Company snapshot
    • 7.9.4. Operating business segments
    • 7.9.5. Product portfolio
  • 7.10. Venus MedTech HangZhou Inc.
    • 7.10.1. Company overview
    • 7.10.2. Key executives
    • 7.10.3. Company snapshot
    • 7.10.4. Operating business segments
    • 7.10.5. Product portfolio
    • 7.10.6. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
  • TABLE 02. TAVR EMBOLIC PROTECTION MARKET FOR SENTINEL CEREBRAL PROTECTION SYSTEM, BY REGION, 2022-2032 ($THOUSAND)
  • TABLE 03. TAVR EMBOLIC PROTECTION MARKET FOR TRIGUARD 3 CEP DEVICE TECHNOLOGY, BY REGION, 2022-2032 ($THOUSAND)
  • TABLE 04. TAVR EMBOLIC PROTECTION MARKET, BY REGION, 2022-2032 ($THOUSAND)
  • TABLE 05. NORTH AMERICA TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
  • TABLE 06. NORTH AMERICA TAVR EMBOLIC PROTECTION MARKET, BY COUNTRY, 2022-2032 ($THOUSAND)
  • TABLE 07. U.S. TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
  • TABLE 08. CANADA TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
  • TABLE 09. EUROPE TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
  • TABLE 10. EUROPE TAVR EMBOLIC PROTECTION MARKET, BY COUNTRY, 2022-2032 ($THOUSAND)
  • TABLE 11. GERMANY TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
  • TABLE 12. FRANCE TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
  • TABLE 13. UK TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
  • TABLE 14. ITALY TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
  • TABLE 15. REST OF EUROPE TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
  • TABLE 16. ASIA-PACIFIC TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
  • TABLE 17. ASIA-PACIFIC TAVR EMBOLIC PROTECTION MARKET, BY COUNTRY, 2022-2032 ($THOUSAND)
  • TABLE 18. JAPAN TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
  • TABLE 19. CHINA TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
  • TABLE 20. INDIA TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
  • TABLE 21. AUSTRALIA TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
  • TABLE 22. REST OF ASIA-PACIFIC TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
  • TABLE 23. LAMEA TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
  • TABLE 24. LAMEA TAVR EMBOLIC PROTECTION MARKET, BY COUNTRY, 2022-2032 ($THOUSAND)
  • TABLE 25. LATIN AMERICA TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
  • TABLE 26. MIDDLE EAST AND AFRICA TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022-2032 ($THOUSAND)
  • TABLE 27. BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
  • TABLE 28. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • TABLE 29. BOSTON SCIENTIFIC CORPORATION: PRODUCT SEGMENTS
  • TABLE 30. BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
  • TABLE 31. EDWARD LIFESCIENCES CORPORATION: KEY EXECUTIVES
  • TABLE 32. EDWARD LIFESCIENCES CORPORATION: COMPANY SNAPSHOT
  • TABLE 33. EDWARD LIFESCIENCES CORPORATION: PRODUCT SEGMENTS
  • TABLE 34. EDWARD LIFESCIENCES CORPORATION: PRODUCT PORTFOLIO
  • TABLE 35. FILTERLEX MEDICAL LTD.: KEY EXECUTIVES
  • TABLE 36. FILTERLEX MEDICAL LTD.: COMPANY SNAPSHOT
  • TABLE 37. FILTERLEX MEDICAL LTD.: PRODUCT SEGMENTS
  • TABLE 38. FILTERLEX MEDICAL LTD.: PRODUCT PORTFOLIO
  • TABLE 39. FILTERLEX MEDICAL LTD.: KEY STRATERGIES
  • TABLE 40. PROTEMBIS GMBH: KEY EXECUTIVES
  • TABLE 41. PROTEMBIS GMBH: COMPANY SNAPSHOT
  • TABLE 42. PROTEMBIS GMBH: PRODUCT SEGMENTS
  • TABLE 43. PROTEMBIS GMBH: PRODUCT PORTFOLIO
  • TABLE 44. PROTEMBIS GMBH: KEY STRATERGIES
  • TABLE 45. INNOVATIVE CARDIOVASCULAR SOLUTIONS, LLC.: KEY EXECUTIVES
  • TABLE 46. INNOVATIVE CARDIOVASCULAR SOLUTIONS, LLC.: COMPANY SNAPSHOT
  • TABLE 47. INNOVATIVE CARDIOVASCULAR SOLUTIONS, LLC.: PRODUCT SEGMENTS
  • TABLE 48. INNOVATIVE CARDIOVASCULAR SOLUTIONS, LLC.: PRODUCT PORTFOLIO
  • TABLE 49. ENCOMPASS TECHNOLOGIES, INC.: KEY EXECUTIVES
  • TABLE 50. ENCOMPASS TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • TABLE 51. ENCOMPASS TECHNOLOGIES, INC.: PRODUCT SEGMENTS
  • TABLE 52. ENCOMPASS TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
  • TABLE 53. ENCOMPASS TECHNOLOGIES, INC.: KEY STRATERGIES
  • TABLE 54. TRANSVERSE MEDICAL INC.: KEY EXECUTIVES
  • TABLE 55. TRANSVERSE MEDICAL INC.: COMPANY SNAPSHOT
  • TABLE 56. TRANSVERSE MEDICAL INC.: PRODUCT SEGMENTS
  • TABLE 57. TRANSVERSE MEDICAL INC.: PRODUCT PORTFOLIO
  • TABLE 58. EMBOLINE, INC.: KEY EXECUTIVES
  • TABLE 59. EMBOLINE, INC.: COMPANY SNAPSHOT
  • TABLE 60. EMBOLINE, INC.: PRODUCT SEGMENTS
  • TABLE 61. EMBOLINE, INC.: PRODUCT PORTFOLIO
  • TABLE 62. EMBOLINE, INC.: KEY STRATERGIES
  • TABLE 63. CARDIOPTIMUS: KEY EXECUTIVES
  • TABLE 64. CARDIOPTIMUS: COMPANY SNAPSHOT
  • TABLE 65. CARDIOPTIMUS: PRODUCT SEGMENTS
  • TABLE 66. CARDIOPTIMUS: PRODUCT PORTFOLIO
  • TABLE 67. VENUS MEDTECH HANGZHOU INC.: KEY EXECUTIVES
  • TABLE 68. VENUS MEDTECH HANGZHOU INC.: COMPANY SNAPSHOT
  • TABLE 69. VENUS MEDTECH HANGZHOU INC.: PRODUCT SEGMENTS
  • TABLE 70. VENUS MEDTECH HANGZHOU INC.: PRODUCT PORTFOLIO
  • TABLE 71. VENUS MEDTECH HANGZHOU INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. TAVR EMBOLIC PROTECTION MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF TAVR EMBOLIC PROTECTION MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN TAVR EMBOLIC PROTECTION MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN TAVR EMBOLIC PROTECTION MARKET (2023-2032)
  • FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 07. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL TAVR EMBOLIC PROTECTION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. TAVR EMBOLIC PROTECTION MARKET, BY PRODUCT, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF TAVR EMBOLIC PROTECTION MARKET FOR SENTINEL CEREBRAL PROTECTION SYSTEM, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF TAVR EMBOLIC PROTECTION MARKET FOR TRIGUARD 3 CEP DEVICE TECHNOLOGY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. TAVR EMBOLIC PROTECTION MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 15. U.S. TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
  • FIGURE 16. CANADA TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
  • FIGURE 17. GERMANY TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
  • FIGURE 18. FRANCE TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
  • FIGURE 19. UK TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
  • FIGURE 20. ITALY TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
  • FIGURE 21. REST OF EUROPE TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
  • FIGURE 22. JAPAN TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
  • FIGURE 23. CHINA TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
  • FIGURE 24. INDIA TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
  • FIGURE 25. AUSTRALIA TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
  • FIGURE 26. REST OF ASIA-PACIFIC TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
  • FIGURE 27. LATIN AMERICA TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
  • FIGURE 28. MIDDLE EAST AND AFRICA TAVR EMBOLIC PROTECTION MARKET, 2022-2032 ($THOUSAND)
  • FIGURE 29. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
  • FIGURE 30. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
  • FIGURE 31. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
  • FIGURE 32. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 33. COMPETITIVE DASHBOARD
  • FIGURE 34. COMPETITIVE HEATMAP: TAVR EMBOLIC PROTECTION MARKET
  • FIGURE 35. TOP PLAYER POSITIONING, 2022
  • FIGURE 36. BOSTON SCIENTIFIC CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 38. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 39. EDWARD LIFESCIENCES CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. EDWARD LIFESCIENCES CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 41. EDWARD LIFESCIENCES CORPORATION: REVENUE SHARE BY REGION, 2022 (%)